Research conducted by Dr. Xingli Deng and his team at Kunming Medical University has uncovered a significant connection between hormonal imbalances, gut microbiota, and cognitive deficits in patients with pituitary neuroendocrine tumors (PitNETs). This study, published in the Chinese Neurosurgical Journal on 30 December 2025, highlights how these factors contribute to cognitive impairments experienced by many patients, particularly in memory, attention, and executive function.
Traditionally, cognitive deficits in PitNET patients have been attributed to the physical effects of tumor mass and pressure on surrounding brain structures. However, as the research indicates, hormonal dysregulation and changes in gut microbiota may play a more crucial role in impacting cognitive function. The study aimed to explore these connections through a prospective cross-sectional analysis involving 42 patients diagnosed with PitNETs and an equal number of matched healthy controls.
Utilizing the Montreal Cognitive Assessment (MoCA), researchers evaluated cognitive function both prior to surgery and three months post-operation. The study also assessed tumor characteristics, including volume and invasiveness, alongside hormone levels in the blood. Tumors were classified as functional or nonfunctional and further categorized by their molecular lineage, specifically PIT1 and SF-1 lineages.
The findings were striking. Patients with PitNETs scored significantly lower on cognitive assessments compared to healthy controls, particularly in areas of attention and executive function. The deficits were found to be most pronounced in those with functional tumors and specifically in those classified under the PIT1 lineage. Notably, tumor size and invasiveness did not correlate with cognitive performance, challenging previous assumptions about the primary causes of cognitive decline.
Three months after surgical intervention, cognitive scores showed improvement, coinciding with reductions in elevated hormone levels such as growth hormone (GH), insulin-like growth factor 1 (IGF-1), and prolactin (PRL). These results suggest an endocrine mechanism that may underlie both cognitive dysfunction and potential recovery.
In parallel, the microbiome analysis revealed distinct differences in gut bacteria composition among the patients. A notable decrease in the abundance of the butyrate-producing genus Agathobacter, known for its anti-inflammatory properties, was observed. Conversely, there was an increase in potentially pro-inflammatory bacteria, such as Alistipes indistinctus and UBA1819. These alterations may indicate that inflammatory and metabolic pathways linked to gut microbiota could interact with hormonal imbalances to affect cognitive outcomes.
This comprehensive study not only integrates clinical, endocrine, cognitive, and microbiome data but also moves beyond traditional models that focus solely on tumor characteristics. By linking tumor lineage and gut microbiota changes to cognitive impairment, the research proposes a multifactorial model that emphasizes both hormonal and microbiomic influences.
While the sample size remains modest, and the cross-sectional design limits definitive causality conclusions, the findings pave the way for larger longitudinal studies. Such research could clarify the relationships between these factors and explore the potential for microbiota-targeted interventions to enhance cognitive outcomes post-surgery.
In summary, cognitive impairment is prevalent among patients with PitNETs, particularly those with tumors of the PIT1 lineage. The study indicates that cognitive dysfunction correlates more strongly with hormonal dysregulation and changes in gut microbiota than with conventional measures of tumor burden. The insights gained from this research may lead to new therapeutic approaches that address both cognitive function and quality of life for individuals affected by PitNETs.
